Live data · NADAC + Part D CY24 · reviewed daily

Alendronate and Cholecalciferol (FOSAMAX PLUS D)

Vitamin D class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2021-06-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$52.51/unit
2 NDCs benchmarked, lowest of all strengths.
Average NADAC
$52.54
Across all dosage forms in distribution.
Highest NADAC
$52.56
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Alendronate and Cholecalciferol used for?

Alendronate and Cholecalciferol is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Alendronate and Cholecalciferol?

No. Alendronate and Cholecalciferol is brand-only with no generic equivalents currently in market.

How much does my plan pay for Alendronate and Cholecalciferol?

Across 329 Part D plans, Alendronate and Cholecalciferol averages $52.54/unit (NADAC). Lowest available: $52.51/unit. Highest in distribution: $52.56/unit.

Is Alendronate and Cholecalciferol on the FDA shortage list?

No. Alendronate and Cholecalciferol is not currently on the FDA Drug Shortage Database.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (2 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.